Mimic peptides of gp120
CA 2111681 A1 · Owner: Immulogic Pharmaceutical Corporation · Inventors: Gefter, Malcolm L.; Melmon, Kenneth L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are peptides having a primary amino acid sequence which is unrelated to gp120. The peptides are characterized by the ability to stimulate the production of anti-gp120 particularly, anti-V3-loop, antibodies when administered to a mammal. The peptides are also characterized by the ability to interfere with viral function. The peptides can be formulated as a vaccine composition and administered as a method for stimulating an HIV-1 neutralizing immune response.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 19, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 19, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 19, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.